Back to results
US 5,817,693 AGranted
Endothelin receptor antagonists
OwnerRussell Donovan Cousins, John Duncan Elliott +3inventors
InventorsRussell Donovan Cousins, John Duncan Elliott, Maria Amparo Lago, Jack Dale Leber, Catherine Elizabeth Peishoff
Life of this patent
Estimating the term…
Abstract
Novel indane and indene derivatives are described which are endothelin receptor antagonists.
Claims24
A compound of Formula (I):
- ##STR21## wherein:
- R.sub.1 is --X(CH.sub.2).sub.n Ar, dihydrobenzofuranyl, benzodioxanyl, cyclohexyl or C.sub.1-4 alkyl, wherein Ar is a moiety of formula (a) or (b);
- R.sub.2 is a moiety of formula (a) or (b);
- --NH(CO)CH.sub.3 or S(O)qC.sub.1-5 alkyl;
- R.sub.6 is independently hydrogen or C.sub.1-4 alkyl;
- R.sub.7 is independently hydrogen or C.sub.1-10 alkyl, C.sub.2-10 alkenyl, C.sub.2-8 alkynyl, all of which may be unsubstituted or substituted by one or two OH, N(R.sub.6).sub.2, CO.sub.2 R.sub.12, Br, Cl, I, F or XC.sub.1-5 alkyl;
- or R.sub.7 is (CH.sub.2).sub.n Ar;
- R.sub.8 is independently R.sub.11, CO.sub.2 R.sub.7, CO.sub.2 C(R.sub.13).sub.2 O(CO)XR.sub.7, PO.sub.3 (R.sub.7).sub.2, SO.sub.2 NR.sub.7 R.sub.11, NR.sub.7 SO.sub.2 R.sub.11, CONR.sub.7 SO.sub.2 R.sub.11, SO.sub.3 R.sub.7, SO.sub.2 R.sub.7, P(O)(OR.sub.7)R.sub.7, CN,
- --CO.sub.2 (CH.sub.2).sub.m C(O)N(R.sub.6).sub.2, C(R.sub.11).sub.2 N(R.sub.7).sub.2, C(O)N(R.sub.6).sub.2, tetrazole or OR.sub.6, provided that R.sub.11 is not hydrogen in NR.sub.7 SO.sub.2 R.sub.11 or CONR.sub.7 SO.sub.2 R.sub.11, and further provided that R.sub.7 is not hydrogen in SO.sub.3 R.sub.7 or SO.sub.2 R.sub.7 ;
- R.sub.9 is a bond, C.sub.1-10 alkylene, C.sub.1-10 alkylidene, C.sub.2-10 alkenylene, C.sub.2-10 alkynylene, all of which may be linear or branched, or R.sub.9 is phenylene, all of which may be unsubstituted or substituted by one or more OH, N(R.sub.6).sub.2, COOH Br, F, Cl or I;
- R.sub.10 is hydrogen;
- R.sub.11 is hydrogen, Ar, C.sub.1-8 alkyl, C.sub.2-6 alkenyl or C.sub.2-8 alkynyl, all of which may be unsubstituted or substituted by one or two OH, CH.sub.2 OH, N(R.sub.6).sub.2 Br, Cl, F or I;
- R.sub.12 is hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl or C.sub.2-7 alkynyl;
- R.sub.13 is divalent Ar, C.sub.1-10 alkylene, C.sub.1-10 alkylidene, C.sub.2-10 alkenylene, C.sub.2-10 alkynylene, all of which may be unsubstituted or substituted by one or two OH, CH.sub.2 OH, N(R.sub.6).sub.2 Br, Cl, F or I;
- X is (CH.sub.2).sub.n or oxygen;
- Y is CH.sub.3 or X(CH.sub.2).sub.n Ar;
- Ar is:
- ##STR22## or pyridyl, all of which may be substituted or unsubstituted by one or two OH, C.sub.1-5 alkoxy, I, Br, F, Cl, --OC.sub.1-4 alkylphenyl, R.sub.13 CO.sub.2 R.sub.7, C.sub.1-4 alkyl, --N(R.sub.6).sub.2, --NH(CO)CH.sub.3,
- --X(CH.sub.2).sub.n R.sub.8, --X--R.sub.9 --Y, pyridyl, phenyl or S(O)qC.sub.1-5 alkyl, provided that when R.sub.13, R.sub.8 or Y are Ar, the Ar is not substituted by another Ar which is further substituted by an yet another Ar;
- A is C.dbd.O, or (C(R.sub.6).sub.2).sub.m ;
- B is --CH.sub.2 -- or --O--;
- Z.sub.1, Z.sub.2 and Z.sub.3 are independently --X.multidot.R.sub.9 --Y, benzyl, hydrogen, OH, C.sub.1-5 alkoxy, N(R.sub.6).sub.2, S(O)qC.sub.1-8 alkyl, NHCOR.sub.6, X(CH.sub.2).sub.n R.sub.8 or halogen, or Z.sub.1 and Z.sub.2 together may be --O--A--O-- on contiguous carbons;
- P.sub.1 is CO.sub.2 H, C(R.sub.6).sub.2 COOH or tetrazole;
- P.sub.2 is hydrogen,
- q is zero, one or two;
- n is an integer from 0 to 6;
- and
- m is 1, 2 or 3;
- or a pharmaceutically acceptable salt thereof;
- provided that
- when Z.sub.1, Z.sub.2, or Z.sub.3 is X(CH.sub.2).sub.n R.sub.8 and n is not 0, X is oxygen when R.sub.8 is OR.sub.6 or CO.sub.2 H;
- and further provided that
- the compound of Formula I is not +(1S,2R,3S)-3-(2-Carboxymethoxy-4-methoxyphenyl)-1-(3,4-methylenedioxyphen yl)-5-(prop-1-yloxy)-indane-2-carboxylic acid, (cis,cis)-(1RS,3SR)-1,3-diphenylindane-2-carboxylic acid;
- 3(2-carboxymethoxy-4-methoxyphenyl)-1-(3,4-methylenedioxyphenyl)-5-(prop-1 -yloxy)indane-2-carboxylic acid;
- (+)Methyl-(1S,2S,3S)-3-(4-methoxy-2-methoxymethoxyphenyl)-1-(3,4-methylene dioxyphenyl)-5-(prop-1-yloxy)indane-2-carboxylate;
- (+)Methyl-(1S,2S,3S)-3-(2-Hydroxy-4-methoxyphenyl)-1-(3,4-methylenedioxyph enyl)-5-(prop-1-yloxy)indane-2-carboxylate;
- (+)Methyl-(1S,2S,3S)-3-(2-Carboethoxymethoxy-4-methoxyphenyl)-1-(3,4-methy lenedioxyphenyl)-5-(prop-1-yloxy)indane-2-carboxylate;
- or Methyl(1SR,2SR,3SR)-3-2-(2-hydroxyeth-1-yloxy)-4-methoxyphenyl!-1-(3,4-me thylenedioxy phenyl)-5-propoxyindane-2-carboxylate.
35 more elements
Dependencies are inferred from the claim text.